Sublingual Naloxone Spray Formulation for Opioid Overdose
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current naloxone formulations for treating opioid dependence, overdose, and congenital insensitivity to pain with anhidrosis face challenges such as low bioavailability, rapid metabolism leading to frequent dosing, and discomfort, as well as enteral administration issues like hepatic first-pass metabolism and potential addiction concerns with other treatments.
Innovation Solution
Development of storage-stable sublingual spray formulations containing naloxone, its pharmaceutically acceptable salts, or derivatives, with water and an antioxidant, either with or without alcohol, to enhance bioavailability and stability, suitable for children and patients in alcohol recovery, using specific cosolvent and antioxidant combinations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If naloxone is administered orally or via enteral route, then it is easy to administer, but bioavailability is low due to hepatic first-pass metabolism
Solution Approach 1:
The patent uses sublingual mucosa as an intermediary absorption route, bypassing hepatic first-pass metabolism. The formulation contains naloxone in a sublingual spray that allows direct absorption through the sublingual mucosa into systemic circulation, avoiding the liver's first-pass effect while maintaining ease of administration.
Solution Approach 2:
The patent changes the administration parameter from oral/enteral to sublingual, and modifies the formulation parameters by including specific cosolvents (ethanol, propylene glycol, polyethylene glycol) and antioxidants to enhance stability and absorption. This parameter change achieves both high bioavailability and ease of administration.
2Quantity of substance
If naloxone is administered parentally (intravenously or by injection), then bioavailability is high, but patient discomfort increases and frequent dosing is required due to low serum half-life
Solution Approach 1:
The sublingual mucosa serves as an intermediary absorption site that provides high bioavailability similar to parenteral routes but without the discomfort of injections. The formulation enables direct entry of naloxone into systemic circulation through the rich vascular supply of the sublingual area.
Solution Approach 2:
The patent replaces the mechanical injection system with a non-invasive sublingual spray system. This substitution maintains high bioavailability while eliminating patient discomfort associated with needles and injections.
3Duration of action of stationary object
If naloxone formulations are made storage stable, then shelf life is extended, but formulation complexity increases requiring specific cosolvents and antioxidants
Solution Approach 1:
The patent creates a composite formulation system combining naloxone with specific cosolvents (ethanol, propylene glycol, polyethylene glycol) and antioxidants. This composite approach ensures storage stability by protecting naloxone from degradation while maintaining its pharmacological activity.
Solution Approach 2:
The patent optimizes formulation parameters including pH, cosolvent ratios, and antioxidant concentrations to achieve storage stability. By carefully controlling these parameters, the formulation remains stable without excessive complexity.
4Stability of the object's composition
If alcohol is included in sublingual spray formulations, then stability and droplet distribution are improved, but applicability to children and alcohol recovery patients is reduced
Solution Approach 1:
The patent develops alcohol-free formulations that achieve stability and effective droplet distribution through alternative cosolvent systems (propylene glycol, polyethylene glycol). This universal formulation can be safely administered to all patient groups including children and alcohol recovery patients.
Solution Approach 2:
The patent changes the solvent parameter by replacing alcohol with alternative cosolvents that provide comparable or superior stability and droplet characteristics. This parameter change expands the formulation's applicability to vulnerable patient populations.
Data Source
AI summary
The invention provides storage stable sublingual formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering the sublingual formulations of the present invention to a patient in need thereof.